Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

TARDOX: Targeted chemotherapy using focused ultrasound for liver tumours

TARDOX :A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours

CAMELLIA: Anti-CD47 antibody terapy in relapsed/refractory Haematological Malignancies

CAMELLIA: A Phase I dose escalation trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia

ATOM: Atovaquone as Tumour HypOxia Modifier

ATOM: Pre-operative window of opportunity study of the effects of atovaquone on hypoxia in non-small cell lung carcinoma.

6MP: A Phase II Clinical Trial in Patients with BRCA Defective Tumours

6MP: Phase II Clinical Trial Of 6-Mercaptopurine (6MP) And Low-Dose Methotrexate in Patients with known BRCA Defective Tumours

AspECT: A Phase III, Randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia

AspECT: A Phase III, Randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia

BKM120: Palliative thoracic radiotherapy plus BKM120

BKM120: A phase I dose escalation study of the PI3K inhibitor BKM120, given concomitantly with palliative radiotherapy for the treatment of Non-Small Cell Lung Cancer (NSCLC).

CHOP-OR: Study of CHOP with Ofatumumab in Patients with Richter's Syndrome

CHOP-OR: Phase 2 single arm multi-centre feasibility study of CHOP combined with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome

COG : Gefitinib for oesophageal cancer progressing after chemotherapy

COG: Randomised Phase 3 trial of gefitnib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy

DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring

DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring

DEBIOC: Dual Erb B Inhibition in Oesophago-gastric Cancer

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

Load More